Press Release: 2/9/2026
Moulton, Massachusetts Members Demand Accountabilty After Trump Administration Moves to Dismatnle ARPA-H Investor Catalyst Hub
February 7, 2026
SALEM, MA – Today, Congressman Seth Moulton (MA-06) joined with Senators Elizabeth Warren (D-MA) and Ed Markey (D-MA) and Representatives Lori Trahan (MA-03), Jake Auchincloss (MA-04), Stephen F. Lynch (MA-08), Seth Moulton (MA-06), and Richard E. Neal (MA-01) in demanding immediate answers from the Trump Administration following reports that the Advanced Research Projects Agency for Health (ARPA-H) has issued a stop-work order and notice of intent to terminate and wind down the ARPA-H Investor Catalyst Hub.
In a letter to President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr., the lawmakers called for an immediate explanation and justification for the decision, warning it could disrupt lifesaving biomedical innovation and waste years of federal investment.
“Terminating the Investor Catalyst Hub’s work at this stage would be a profound mistake and a blatant waste of taxpayer dollars and federal investment,” the lawmakers wrote. “Halting this work now would squander years of progress, disrupt momentum across multiple ARPA-H programs, and undermine the agency’s core mission of translating high-impact research into treatments and cures that reach the American people.”
The Investor Catalyst Hub, based in the greater Boston area, plays a central role in ensuring promising innovations successfully transition from federal research investment into real-world treatments and cures. The Hub was strategically located in Massachusetts because of the Commonwealth’s globally recognized life sciences and biotechnology ecosystem, and unmatched concentration of research institutions, hospitals, and health innovators.
Congress recently reaffirmed its commitment to ARPA-H by appropriating $1.5 billion in fiscal year 2026 funding to accelerate high-impact biomedical innovation and strengthen pathways that move breakthroughs from discovery to deployment. The delegation noted that the Investor Catalyst Hub has been fully operational for two years and is already supporting projects focused on improving cancer surgery, expanding hospital-level care to rural communities, and advancing the diagnosis and treatment of lymphatic diseases.
“With Congress' support, the Investor Catalyst Hub was created precisely to ensure that ARPA-H–funded breakthroughs do not stall out in the lab but instead move efficiently toward real-world deployment,” the lawmakers continued.
The members requested a congressional briefing, a clear justification for the decision, and a detailed contingency plan explaining how ARPA-H will maintain continuity of the Investor Catalyst Hub’s work. They asked the Administration to respond no later than February 13, 2026.
A copy of the letter sent today can be accessed HERE.